Daniel B. Costa
Expertise in
14
conditions

Dr. Daniel B. Costa

Oncology
330 Brookline Avenue, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
14
conditions
330 Brookline Avenue, 
Boston, MA 

Overview

Daniel Costa is an Oncologist practicing medicine in Boston, Massachusetts.

Dr. Costa is highly rated in 14 conditions, according to our data. His clinical expertise encompasses EGFR Positive Lung Cancer, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma.

Dr. Costa is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 149 peer reviewed articles and participating in 12 clinical trials. Dr. Costa is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MA

Board Certifications

American Board Of Internal Medicine

Fellowships

Beth Israel Deaconess Medical Center

Hospital Affiliations

Beth Israel Deaconess Hospital - Needham
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Hospital Plymouth

Languages Spoken

English
Portuguese

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Boston, MA 02215

Additional Areas of Focus

Dr. Costa has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Lung Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drugs: Osimertinib, Selumetinib
Study Phase: Phase 2
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: March 04, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients With Advanced, ALK-Positive, Non-Small Cell Lung Cancer
A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients With Advanced, ALK-Positive, Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: May 13, 2025
Intervention Type: Drug
Study Drugs: Alectinib, Bevacizumab
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
A Phase 1/2 Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Enrollment Status: Terminated
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer
A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: November 04, 2020
Intervention Type: Drug
Study Phase: Phase 2
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation
Enrollment Status: Unknown
Publish Date: July 07, 2020
Intervention Type: Drug
Study Drug: Afatinib
Study Phase: Phase 2
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Enrollment Status: Terminated
Publish Date: November 22, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity
A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity
Enrollment Status: Completed
Publish Date: October 31, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

149 Total Publications

Coopting Germline BRCA2 Mutation With an Available PARP Inhibitor to Manage Resistance to EGFR Targeted Therapy in EGFR-Mutated Lung Cancer: Combination of Olaparib With Osimertinib.
Coopting Germline BRCA2 Mutation With an Available PARP Inhibitor to Manage Resistance to EGFR Targeted Therapy in EGFR-Mutated Lung Cancer: Combination of Olaparib With Osimertinib.
Journal: Clinical lung cancer
Published: January 20, 2026
Similar Doctors
Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.2 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Davids is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Davids is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Aspiration, and Tissue Biopsy. Dr. Davids is currently accepting new patients.

Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (2.5 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeremy Abramson is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Abramson is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Abramson is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (0.2 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Toni Choueiri is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Choueiri is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Urothelial Cancer, Nephrectomy, and Orchiectomy. Dr. Choueiri is currently accepting new patients.

Frequently Asked Questions about Dr. Daniel B. Costa

How do I make an appointment with Dr. Daniel B. Costa?

You can book an appointment with Dr. Daniel B. Costa by calling their office at 617-667-9236. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel B. Costa a top-rated expert for EGFR Positive Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel B. Costa is classified as an Elite expert for EGFR Positive Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel B. Costa specialize in?

While Dr. Daniel B. Costa is a Oncology, they have specific expertise in EGFR Positive Lung Cancer, Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Daniel B. Costa participate in research or clinical trials?

Yes. Dr. Daniel B. Costa has published 149 articles and abstracts on conditions like EGFR Positive Lung Cancer. You can view a list of Dr. Daniel B. Costa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel B. Costa accept my insurance?

Dr. Daniel B. Costa accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-667-9236 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Costa's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile